The drugmaker plans to enroll 60 people in the study, all of whom previously got both doses of the original vaccine. The volunteers will receive either the new vaccine designed to combat the virus variant first found in South Africa, called B.1.351, or a single shot that contains both the variant vaccine and original vaccine, according to the Journal.
Moderna will also test if giving volunteers a third dose of the original vaccine can protect against the variants. If data from the trial is positive, the drugmaker could seek regulatory approval in the third quarter, the Journal reported.
The National Institutes of Health is also planning to study Moderna’s variant vaccine in people who didn’t get the original vaccine, The Hill reported.
More articles on pharmacy:
US will purchase 100M more J&J vaccines
Very few severe allergic reactions tied to mRNA vaccines, research shows
Pfizer’s newest vaccine manufacturing site has history of mold, recall troubles
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
